Afinitor Approval Expanded to Include Benign Kidney Tumors
FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food and Drug Administration to treat benign kidney tumors among people with a rare genetic condition called tuberous sclerosis complex (TSC), the agency said in a news release.
TSC causes non-cancerous tumors of the brain, kidney and other organs, the FDA said. The disease affects up to 40,000 people in the United States, and as many as 80 percent develop kidney problems.
Afinitor helps suppress these tumors by blocking a protein that's essential for their development and growth, the FDA said.
The drug's safety and effectiveness were clinically evaluated among 118 people with TSC. The most common side effects were inflamed or sore mouth, nausea and vomiting, acne, eczema, cough, headache, diarrhea, abdominal pain, joint pain and swelling of the legs or arms. Some 15 percent of females who took Afinitor missed at least one menstrual period.
Afinitor was first approved by the FDA in 2009 to treat kidney tumors that weren't treated successfully with other drugs.
Afinitor is produced by Novartis, based in East Hanover, N.J.
More information
To learn more about this drug, visit the U.S. National Cancer Institute.
Related Articles- Statins Plus Certain Antibiotics May Set Off Toxic Reaction: Study
June 17, 2013 - New Silicone Breast Implants Approved
June 14, 2013
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2012 HealthDay. All rights reserved.
Sharp HealthCare is a 2007 Malcolm Baldrige National Quality Award Recipient